Wikipedia
Tetulomab
Tetulomab (HH1) is a murine monoclonal antibody against glycoprotein CD37, which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital and as of 2014 was under development by the Norwegian company Nordic Nanovector as a radioimmunotherapeutic in which tetulomab is conjugated to a radiation-emitting isotope of lutetium, Lu; that form of the drug is called Lu-HH1 or lutetium (Lu) tetulomab tetraxetan (trade name Betalutin). As of 2014, a phase I/II clinical trial in people with non-Hodgkin lymphoma was underway.